Month: February 2024

Strong 2023 performance and a solid start to the Company’s three-year strategic planAnnual sales of $3,319 million, up 8%, driven by 13% organic sales growth in infrastructure product categories Record increase in 2023 EBITDA(1), up 36% to $608 million, or a margin(1) of 18.3% Annual net income of $326 million, or $5.62 per share, up 43% from 2022 EPS Quarterly cash dividend increased by 22% to $0.28 per share Leadership position strengthened by strategic capacity-enhancing investmentsMONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) — Stella-Jones Inc. (TSX: SJ) (“Stella-Jones” or the “Company”) today announced financial results for its fourth quarter and year ended December 31, 2023. “We concluded 2023 with a marked improvement in profitability and the successful execution of investments to support the continued growth...

IRVINE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global provider of compute and connectivity IoT solutions, today announced the appointment of Kurt Hoff as its vice president, Worldwide Sales, effective March 4, 2024. Hoff will replace Roger Holliday, vice president of Worldwide Sales at Lantronix, who is stepping down on Feb. 29, 2024, in order to retire. “We are very pleased to welcome Kurt Hoff to the Lantronix leadership team,” said Saleel Awsare, president and CEO of Lantronix. “Kurt’s knowledge and experience in the IoT industry, coupled with his abilities in scaling IoT revenue and profitability at industry leaders such as Silicon Labs, Synaptics and Conexant, makes him an excellent addition to the Lantronix team.” Prior to his appointment to Lantronix, Hoff served as senior vice president...

MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 16,666,667 of its common shares (the “Shares”) at a public offering price of $1.50 per share and (ii) in lieu of common shares, pre-funded warrants to purchase 3,333,333 common shares at a public offering price of $1.49 per pre-funded warrant, which represents the per share public offering price for the Shares less the $0.001 per share exercise price for each such pre-funded warrant (“Pre-Funded Warrants” and, together with the Shares the “Securities”). The proceeds to Milestone from...

GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023. Emergent’s newly appointed president and CEO, Joseph C. Papa, will provide remarks. Conference Call InformationParticipants can access the conference call live via webcast from the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can be accessed from the Investors page of Emergent’s...

All figures quoted in U.S. dollars unless otherwise noted:2023 Q4 revenue of $792 million; 1,227 equivalent units (“EUs”) delivered, up 19% from 2022 Q4, with 236 of EUs delivered being battery- and fuel cell-electric buses (“ZEBs”). Full year revenue of $2.7 billion; 4,001 EUs delivered, with 22% ZEBs. 2023 Q4 Net loss of $2 million; Net loss per Share of $0.02, and Adjusted Net Loss per Share2 of $0.05. 2023 Q4 Adjusted EBITDA2 of $39 million and full year Adjusted EBITDA2 of $69 million. Ending Total Liquidity2 position of $188 million. Ending total backlog2 position (both firm and options) of 10,586 EUs (valued at $7.9 billion), with 3,832 EUs in bid award pending; ZEBs represent 36% of total backlog2. Aftermarket segment delivers record 2023 performance with $555 million of revenue, and $120 million of Adjusted...

LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it will release its fourth quarter and full year 2023 results and operational highlights on Thursday March 14, 2024. Management will host a conference call and webcast at 8:30 am EDT/12:30 pm GMT to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive dial-in numbers and a personal PIN, which are required to access the conference call. A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website. Contact: Olivia Manser+44 (0) 7780 471 568o.manser@autolus.com Julia Wilson+44 (0) 7818 430877j.wilson@autolus.com Susan...

LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) — Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (Arqit), a leader in quantum-safe encryption was honoured to receive two Glomo awards at Mobile World Congress on February 28, 2024. The company took home the top honour in the CTO Choice: Outstanding Mobile Technology Award category, which was voted on by CTO’s across the industry, including those from the world’s major mobile phone companies, along with the award for Best Mobile Security Solution. David Williams Arqit Founder said, “Solving one of the biggest technology problems of the era and changing the way that significant parts of the World does encryption is a very large challenge. Arqit software is unique in doing this through symmetric key agreement and rotating authentication at end points in a manner which is not only quantum safe but...

New Composition of Matter Patent for farudodstat would strengthen intellectual property protection and provide commercial exclusivity for farudodstat until at least 2043SAN MATEO, Calif. and SINGAPORE, Feb. 29, 2024 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced it has received a favorable patentability opinion from the European Patent Office (EPO) acting as the International Examiner on a polymorph patent application for farudodstat which, if granted in the national stages, will extend effective patent protection for farudodstat until at least 2043. Farudodstat is a potent, oral dihydroorotate dehydrogenase (DHODH) inhibitor with the potential to be a first-in-class...

MONTVALE, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) — Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate at the BNP Paribas Exane 12th Consumer Ingredients Conference on March 14, 2024. Ted Harris, Chairman of the Board, Chief Executive Officer, and President, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations will participate at the conference. More information will be available on Balchem’s website (www.balchem.com/investor-relations) after the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest quality...

MALVERN, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will report fourth quarter and full year 2023 financial results on Thursday, March 21, 2024. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Fourth Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before...